Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Akebia Therapeutics posts robust Q4 results, eyes expansion opportunities

Akebia Therapeutics showcased a strong performance in Q4 2022, highlighting revenue growth, regulatory progress, and strategic initiatives. The company faces challenges in regulatory processes and funding but is well-positioned to capitalize on opportunities for growth and innovation.

Akebia Therapeutics excels in Q1 2023, faces regulatory challenges

Akebia Therapeutics demonstrated strong performance in Q1 2023 with key achievements in product approvals and clinical study results, while also addressing revenue challenges and cost management.
The company faces challenges related to regulatory compliance and revenue decline but has opportunities to explore new therapeutic applications and strategic partnerships for growth.
Overall, Akebia's proactive approach to addressing challenges and pursuing opportunities positions it well for future success in the competitive biopharmaceutical market.

Akebia Therapeutics advances vadadustat globally, eyes U.S. launch in 2024

Akebia Therapeutics showcased operational progress and financial stability during the Q2 earnings call, emphasizing vadadustat's global potential.
While facing regulatory challenges and competitive pressures, the company's strategic partnerships and leadership confidence signal growth opportunities.
Analysts' inquiries highlighted areas for improvement, suggesting a need for clearer communication and strategic clarity in key operational areas.
Overall, Akebia remains focused on advancing vadadustat towards potential U.S. approval, positioning for future growth and market success.

Akebia Therapeutics reports strong Q3 earnings and readies for vadadustat launch

Akebia Therapeutics is poised for the potential launch of vadadustat with strong financial performance and a well-prepared commercial infrastructure.
The company faces challenges in pricing strategies and market competition but has opportunities to capture a significant share of the anemia treatment market.
Overall, Akebia Therapeutics remains focused on delivering value to patients and shareholders through vadadustat's potential success in the U.S. market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.

Akebia Therapeutics Announces Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.

Akebia Therapeutics to Present at Jefferies London Healthcare Conference

Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Nov. 4, 2021 /PRNewswire/ --  Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate milestones.

Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones

CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors.

Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

CAMBRIDGE, Mass., Oct. 29, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, and its collaborator, Otsuka Pharmaceutical Co., Ltd.

Akebia Announces Otsuka's Submission of Initial Marketing Authorization Application to the European Medicines Agency for Vadadustat for the Treatment of Patients with Anemia due to Chronic Kidney Disease

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

CAMBRIDGE, Mass., Oct. 26, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the third quarter ended September 30, 2021, on Thursday, November 4, 2021 before the opening of the financial markets.

Akebia Therapeutics to Report Third Quarter 2021 Financial Results and Highlight Recent Company Milestones

CAMBRIDGE, Mass., Oct. 18, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that vadadustat efficacy and safety data related to clinical outcomes among patients with anemia due to chronic kidney disease (CKD) will be presented at the American Society of Nephrology Kidney Week 2021 (ASN Kidney Week), which is taking place virtually November 4 – November 7, 2021.

Akebia Announces Vadadustat Efficacy and Safety Data to be Presented at American Society of Nephrology Kidney Week 2021

Alto Ingredients

Babcock & Wilcox Enterprises

Clearsign Combustion

1847 GOEDEKER INC.

Himax Tech

SNDL Inc.

Unwilling to wait for catalysts, some investors threw these small-cap stocks into the garbage bin. But that doesn't mean they won't succeed.

7 Small-Cap Stocks to Buy From the Beat-Up Bargain Bin

CAMBRIDGE, Mass. , Sept. 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.

Akebia Therapeutics Announces September 2021 Investor Conference Schedule

Investors liked what they heard in the company's Q2 update.

Why Akebia Therapeutics Stock Is Soaring Today

Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q2 2021 Results - Earnings Call Transcript

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -70.00% and -11.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) Reports Q2 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass., Aug. 5, 2021 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate milestones.

Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones

OPKO Health

Seelos Therapeutics

Are these biotech penny stocks worth investing in or not? The post 3 Hot Biotech Penny Stocks to Watch With High Volume in 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Biotech Penny Stocks to Watch With High Volume in 2021

LOS ANGELES--(BUSINESS WIRE)---- $AKBA #AKBA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $akba #LawFirm--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of former Keryx Biopharmaceuticals, Inc. (KERX) shareholders who acquired Akebia Therapeutics, Inc. (NASDAQ:AKBA) common stock in the December 2018 transaction by which Keryx became a wholly owned subsidiary of Akebia. Akebia is a biopharmaceutical company that develops and commercializes therapeutics for patients based on hypoxia-inducible factor ("HIF") technology. At the

SHAREHOLDER ALERT: Robbins LLP Announces that Akebia Therapeutics, Inc. (AKBA) is Being Sued for Misleading Keryx Biopharmaceuticals, Inc. (KERX) Shareholders Ahead of Merger

CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2021, on Thursday, August 5, 2021 before the opening of the financial markets.

Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights

Ebang International Holdings

Reddit penny stocks are in focus right now; here's 3 to watch The post These Penny Stocks Are Frequently Talked About on Reddit, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These Penny Stocks Are Frequently Talked About on Reddit, Here's Why

Borqs Technologies

9 Meters Biopharma

Which penny stocks are the best for your watchlist in 2021? The post Best 3 Penny Stocks to Watch Right Now, Worth it or Not?

Best 3 Penny Stocks to Watch Right Now, Worth it or Not?

Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc (NASDAQ: CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ: AKBA) for the development and commercialization of praliciguat. Under the terms of the agreement, Akebia will be solely responsible for the research, development, and commercialization of praliciguat globally.

Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise

CAMBRIDGE, Mass., June 3, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced presentations of data from the global Phase 3 program for vadadustat at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress 2021, to be held June 5 - June 8, 2021.

Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021

Akebia Therapeutics Inc (NASDAQ: AKBA) and its collaborator Otsuka Holdings (OTC: OTSKY) have announced that the FDA has accepted to review vadadustat's marketing application for anemia due to chronic kidney disease. The application covers both adult patients, on dialysis and not on dialysis.

Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia

The stock price of Akebia Therapeutics Inc (NASDAQ: AKBA) increased by over 13% pre-market. This is why it happened.

News for Akebia Therapeutics Stock (AKBA)